Prostate specific antigen (PSA) is an important biomarker to monitor the response to the treatment, but has not been fully utilized as a whole sequence.

Jul 18, 2016 · We used a longitudinal biomarker PSA to discover a new prognostic pattern that predicts castration-resistant prostate cancer (CRPC) after ...

We used a longitudinal biomarker, prostate specific antigen (PSA), to discover a new prognostic pattern that predicts castration-resistant prostate cancer ...

Oct 14, 2024 · Prostate specific antigen (PSA) is an important biomarker to monitor the response to the treatment, but has not been fully utilized as a ...

Jun 18, 2024 · We used a longitudinal biomarker PSA to discover a new prognostic pattern that predicts castration-resistant prostate cancer (CRPC) after ...

We used a longitudinal biomarker PSA to discover a new prognostic pattern that predicts castration-resistant prostate cancer (CRPC) after androgen deprivation ...

Fig. 4. From: Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy.

Dive into the research topics of 'Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy ...

We used a longitudinal biomarker, prostate specific antigen (PSA), to discover a new prognostic pattern that predicts castration-resistant prostate cancer ...

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from ...